Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things. 

Join us in our regular podcast on major industry events in this audio version of Scrip's Five Must-Know Things, this time for the business week ended 6 November 2020.

No surprises that the US presidential election features this week, along with a major oncology acquisition, use of AI in the hunt for COVID drugs, progress in atopic dermatitis, and the opportunity for pharma to rebuild its reputation amid the pandemic. 

 

These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn, and also via Alexa smart speakers. 

Articles mentioned in this episode:

(Also see "President ????: What US Election Uncertainty Means For Biopharma" - Scrip, 4 Nov, 2020.)

(Also see "Sanofi Bids €308m To Buy Kiadis" - Scrip, 2 Nov, 2020.)

(Also see "AI Can Find Many Drugs To Repurpose For COVID-19, But Real-World Results Mixed" - Scrip, 4 Nov, 2020.)

(Also see "Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant" - Scrip, 2 Nov, 2020.)

(Also see "Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity" - Scrip, 30 Oct, 2020.)

 

 

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

SC143278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel